These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 36125928)

  • 21. Permanent prostate brachytherapy monotherapy with I-125 for low- and intermediate-risk prostate cancer: Outcomes in 974 patients.
    Routman DM; Funk RK; Stish BJ; Mynderse LA; Wilson TM; McLaren R; Harmsen WS; Mara K; Deufel CL; Furutani KM; Haddock MG; Pisansky TM; Choo CR; Davis BJ
    Brachytherapy; 2019; 18(1):1-7. PubMed ID: 30293836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Salvage brachytherapy for locally-recurrent prostate cancer after radiation therapy: A comparison of efficacy and toxicity outcomes with high-dose rate and low-dose rate brachytherapy.
    Henríquez López I; González-San Segundo C; Vegas JO; Gutierrez C; Hervas A; Cabeza Rodriguez MÁ; Valero Albarrán J; Rodríguez Villalba S; Álvarez Gonzalez A; Sancho Pardo G; Zapatero A; Álvaro PC
    Radiother Oncol; 2019 Dec; 141():156-163. PubMed ID: 31570236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Salvage brachytherapy for recurrent prostate cancer after definitive radiation therapy: A comparison of low-dose-rate and high-dose-rate brachytherapy and the importance of prostate-specific antigen doubling time.
    Kollmeier MA; McBride S; Taggar A; Anderson E; Lin M; Pei X; Weiji S; Voros L; Cohen G; Yamada Y; Zelefsky MJ
    Brachytherapy; 2017; 16(6):1091-1098. PubMed ID: 28838648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient age as a predictive factor in biochemical recurrence following brachytherapy: Oncological outcomes at a single center.
    Takeuchi S; Iinuma K; Nakano M; Kawase M; Kato D; Kawase K; Takai M; Nakane K; Ito M; Kumano T; Matsuo M; Koie T
    Prostate Int; 2022 Dec; 10(4):224-228. PubMed ID: 36570651
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Comparison of the Biochemical Recurrence risk between Radical Prostatectomy and Brachytherapy in the treatment of low- and intermediate-risk prostate cancer].
    Martínez PF; Belisle DF; Cristallo C; Tobía I; Damia O; Villamil W; Giudice CR
    Arch Esp Urol; 2015 Oct; 68(8):655-60. PubMed ID: 26437328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-dose-rate brachytherapy for the treatment of localised prostate cancer in men with a high risk of disease relapse.
    Laing R; Uribe J; Uribe-Lewis S; Money-Kyrle J; Perna C; Chintzoglou S; Khaksar S; Langley SEM
    BJU Int; 2018 Oct; 122(4):610-617. PubMed ID: 29607601
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Kindts I; Stellamans K; Billiet I; Pottel H; Lambrecht A
    Strahlenther Onkol; 2017 Sep; 193(9):707-713. PubMed ID: 28488030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
    Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
    J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
    Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of five-tiered Gleason grade groups on prognostic prediction in clinical stage T3 prostate cancer undergoing high-dose-rate brachytherapy.
    Tsumura H; Ishiyama H; Tabata KI; Katsumata H; Kobayashi M; Ikeda M; Kurosaka S; Fujita T; Kitano M; Satoh T; Yanagisawa N; Hayakawa K; Iwamura M
    Prostate; 2017 Nov; 77(15):1520-1527. PubMed ID: 28905446
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Implementation of high-dose-rate brachytherapy and androgen deprivation in patients with prostate cancer.
    Lilleby W; Tafjord G; Raabe NK
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):933-9. PubMed ID: 22138456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patients with PSA below 0.2 ng/mL at 8 years post high-dose-rate brachytherapy have an extremely low risk of subsequent recurrence.
    Nakazono M; Urabe F; Iwatani K; Imai Y; Tashiro K; Honda M; Koike Y; Shimomura T; Sato S; Takahashi H; Miki K; Aoki M; Kimura T
    Int J Urol; 2023 Dec; 30(12):1147-1154. PubMed ID: 37650359
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate-specific antigen at 4 to 5 years after low-dose-rate prostate brachytherapy is a strong predictor of disease-free survival.
    Lo AC; Morris WJ; Lapointe V; Hamm J; Keyes M; Pickles T; McKenzie M; Spadinger I
    Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):87-93. PubMed ID: 24331654
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
    Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose-escalated radiation therapy era.
    McGuire SE; Lee AK; Cerne JZ; Munsell MF; Levy LB; Kudchadker RJ; Choi SL; Nguyen QN; Hoffman KE; Pugh TJ; Frank SJ; Corn PG; Logothetis CJ; Kuban DA
    Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):e39-46. PubMed ID: 23102837
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer.
    Morris WJ; Tyldesley S; Rodda S; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N
    Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):275-285. PubMed ID: 28262473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Using a surgical prostate-specific antigen threshold of >0.2 ng/mL to define biochemical failure for intermediate- and high-risk prostate cancer patients treated with definitive radiation therapy in the ASCENDE-RT randomized control trial.
    Morris WJ; Pickles T; Keyes M
    Brachytherapy; 2018; 17(6):837-844. PubMed ID: 30245169
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients.
    Joseph N; Taylor C; O'Hara C; Choudhury A; Elliott T; Logue J; Wylie J
    Radiother Oncol; 2016 Nov; 121(2):299-303. PubMed ID: 28029404
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose escalation with external beam radiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high risk prostate cancer: Comparison of two consecutive high-dose-rate schemes.
    Olarte A; Cambeiro M; Moreno-Jiménez M; Arbea L; Pérez-Gracia JL; Gil-Bazo I; Pascual I; Aristu J; Martínez-Monge R
    Brachytherapy; 2016; 15(2):127-35. PubMed ID: 26832677
    [TBL] [Abstract][Full Text] [Related]  

  • 40. American Brachytherapy Society Task Group Report: Use of androgen deprivation therapy with prostate brachytherapy-A systematic literature review.
    Keyes M; Merrick G; Frank SJ; Grimm P; Zelefsky MJ
    Brachytherapy; 2017; 16(2):245-265. PubMed ID: 28110898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.